Export 5 results:
Author Title [ Type(Asc)] Year
Filters: Author is Abbink, Peter  [Clear All Filters]
Journal Article
D. H. Barouch, Liu, J., Li, H., Maxfield, L. F., Abbink, P., Lynch, D. M., M Iampietro, J., SanMiguel, A., Seaman, M. S., Ferrari, G., Forthal, D. N., Ourmanov, I., Hirsch, V. M., Carville, A., Mansfield, K. G., Stablein, D., Pau, M. G., Schuitemaker, H., Sadoff, J. C., Billings, E. A., Rao, M., Robb, M. L., Kim, J. H., Marovich, M. A., Goudsmit, J., and Michael, N. L., Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys., Nature, vol. 482, no. 7383, pp. 89-93, 2012.
K. Modjarrad, Lin, L., George, S. L., Stephenson, K. E., Eckels, K. H., De La Barrera, R. A., Jarman, R. G., Sondergaard, E., Tennant, J., Ansel, J. L., Mills, K., Koren, M., Robb, M. L., Barrett, J., Thompson, J., Kosel, A. E., Dawson, P., Hale, A., C Tan, S., Walsh, S. R., Meyer, K. E., Brien, J., Crowell, T. A., Blazevic, A., Mosby, K., Larocca, R. A., Abbink, P., Boyd, M., Bricault, C. A., Seaman, M. S., Basil, A., Walsh, M., Tonwe, V., Hoft, D. F., Thomas, S. J., Barouch, D. H., and Michael, N. L., Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trials., Lancet, vol. 391, no. 10120, pp. 563-571, 2018.
L. R. Baden, Liu, J., Li, H., Johnson, J. A., Walsh, S. R., Kleinjan, J. A., Engelson, B. A., Peter, L., Abbink, P., Milner, D. A., Golden, K. L., Viani, K. L., Stachler, M. D., Chen, B. J., Pau, M. G., Weijtens, M., Carey, B. R., Miller, C. A., Swann, E. M., Wolff, M., Loblein, H., Seaman, M. S., Dolin, R., and Barouch, D. H., Induction of HIV-1-specific mucosal immune responses following intramuscular recombinant adenovirus serotype 26 HIV-1 vaccination of humans., J Infect Dis, vol. 211, no. 4, pp. 518-28, 2015.
L. R. Baden, Walsh, S. R., Seaman, M. S., Tucker, R. P., Krause, K. H., Patel, A., Johnson, J. A., Kleinjan, J., Yanosick, K. E., Perry, J., Zablowsky, E., Abbink, P., Peter, L., M Iampietro, J., Cheung, A., Pau, M. G., Weijtens, M., Goudsmit, J., Swann, E., Wolff, M., Loblein, H., Dolin, R., and Barouch, D. H., First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001)., J Infect Dis, vol. 207, no. 2, pp. 240-7, 2013.
L. R. Baden, Walsh, S. R., Seaman, M. S., Johnson, J. A., Tucker, R. P., Kleinjan, J. A., Gothing, J. A., Engelson, B. A., Carey, B. R., Oza, A., Bajimaya, S., Peter, L., Bleckwehl, C., Abbink, P., Pau, M. G., Weijtens, M., Kunchai, M., Swann, E. M., Wolff, M., Dolin, R., and Barouch, D. H., First-in-human evaluation of a hexon chimeric adenovirus vector expressing HIV-1 Env (IPCAVD 002)., J Infect Dis, vol. 210, no. 7, pp. 1052-61, 2014.